Abstract
This randomized, placebo-controlled, 5-week Phase II trial evaluated the safety and tolerability of SIB-1508Y, a selective alpha4beta2 nicotinic acetylcholine receptor agonist, in 77 individuals with early Parkinson disease. Lightheadedness was a common dosage-related adverse effect at higher dosages, leading to frequent dosage reduction, drug discontinuation, and eventual trial redesign. A maximally tolerated dosage of 10 mg daily was identified. No antiparkinsonian or cognitive-enhancing effects were demonstrated in this trial.
Publication types
-
Clinical Trial, Phase II
-
Multicenter Study
-
Randomized Controlled Trial
MeSH terms
-
Aged
-
Antiparkinson Agents / therapeutic use*
-
Dizziness / chemically induced
-
Dose-Response Relationship, Drug
-
Female
-
Humans
-
Male
-
Middle Aged
-
Nicotinic Agonists / administration & dosage
-
Nicotinic Agonists / adverse effects
-
Nicotinic Agonists / therapeutic use*
-
Parkinson Disease / drug therapy*
-
Pyridines / administration & dosage
-
Pyridines / adverse effects
-
Pyridines / therapeutic use*
-
Pyrrolidines / administration & dosage
-
Pyrrolidines / adverse effects
-
Pyrrolidines / therapeutic use*
-
Treatment Outcome
Substances
-
Antiparkinson Agents
-
Nicotinic Agonists
-
Pyridines
-
Pyrrolidines
-
altinicline maleate